Sign in

Constellate

Pre-seed · October 2026 · Biotech & pharma · Europe

What it sells

Constellate Proteomics reads antibody samples one molecule at a time, turning a drop of crude, unpurified supernatant into clone-ranking data (titer, glycosylation, aggregation, charge variant) in minutes instead of weeks.

Business model breakdown

Distribution: how it reaches customers

Pilot program and 'Partner with us' enquiries.

Funding history and coverage

Round dateStageAmountInvestorsSource
2026-10-20Pre-seed——news.google.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-01.

More startups in Biotech & pharma

  1. Formation

    Formation Bio is a tech-driven, AI-native pharma company that acquires and develops clinical-stage assets, and has launched a $600M Drug Development Accelerator Fund.

    $600M · 2026-10-30Biotech & pharmaNorth America

  2. Libo Bio

    Targeted RNA small-molecule drug development

    Series A · nearly CNY 100M · 2026-10-30Biotech & pharmaChina

  3. ALLOX

    ALLOX uses genetics and AI in high-throughput experiments to learn the biophysical parameters governing protein function, mapping functional hotspots to accelerate the discovery…

    Seed · $10.5M · 2026-10-29Biotech & pharmaEurope

  4. StimCardio

    StimCardio Medical is developing a non-invasive wearable neuromodulation platform combining continuous physiological sensing with personalized therapy, starting with atrial…

    Series A · $30M · 2026-10-29Biotech & pharmaOther regions

  5. Coherence Neuro

    Coherence designs therapeutic neurotechnology to manage cancer from inside the body; its flagship SOMA is a brain-computer interface with a wireless coin-sized implant, an…

    Series A · $45M · 2026-10-28Biotech & pharmaNorth America

  6. Samplix

    Single-cell analysis and isolation technology (Xdrop instrument, consumables and digital tools) with applications in immunotherapy, antibody discovery, screening and genomics.

    €25M · 2026-10-28Biotech & pharmaEurope

All startups in this market →